Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Understand the source comparison

ARA-290 Safety Profile: Clinical vs Traditional EPO Comparison

This table compares ARA-290's safety profile with traditional erythropoietin (EPO) across key clinical and hematological endpoints, highlighting the selective tissue-protective action without erythropoietic or cardiovascular liability. Hemoglobin/Hematocrit Ch

No winner is assigned.

This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.

  • This table compares ARA-290's safety profile with traditional erythropoietin (EPO) across key clinical and hematological endpoints, highlighting the selective tissue-protective action without erythropoietic or cardiovascular liability.
  • Hemoglobin/Hematocrit Change
  • No significant change at doses up to 8mg daily for 28 days
  • Dose-dependent increase; target Hb 10–12 g/dL in anemia protocols
  • ARA-290 does not activate classical EPO receptor homodimer responsible for erythropoiesis
  • ARA-290 eliminates hematological risk entirely. No polycythemia, no hematocrit monitoring required
  • Thrombotic Event Risk
  • Zero thrombotic events across Phase 2 trials (n=100+)
  • Increased risk; FDA black box warning for stroke and VTE at Hb >12 g/dL
  • Elevated hemoglobin and blood viscosity drive thrombotic risk with EPO
  • ARA-290's receptor selectivity removes the primary cardiovascular liability that limits EPO use
  • Blood Pressure Effect
  • No clinically significant BP change vs placebo
  • Dose-dependent hypertension in 20–30% of patients; mechanism involves endothelin-1 upregulation
  • EPO's vascular effects driven by classical receptor; ARA-290 does not engage this pathway
  • Blood pressure stability across trials means no cardiovascular monitoring burden
  • Injection Site Reactions
  • Transient erythema in <5% (placebo-equivalent rate)
  • Injection site pain in 10–15%; often related to excipient volume
  • Both require subcutaneous administration; similar local tolerance
  • No meaningful difference. Both well-tolerated at injection site
  • Immunogenicity Risk
  • No antibody formation detected across trials; no loss of efficacy
  • Anti-EPO antibodies rare but catastrophic (pure red cell aplasia) when they occur
  • Short peptide structure may reduce immunogenic epitopes vs full EPO protein
  • Lower theoretical immunogenicity risk, though long-term data still limited

Related resources

More comparisons